Apyx Medical Inc
$ 3.94
1.03%
16 Apr - close price
- Market Cap 164,807,000 USD
- Current Price $ 3.94
- High / Low $ 4.10 / 3.86
- Stock P/E N/A
- Book Value 0.35
- EPS -0.27
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.76 %
- 52 Week High 4.50
- 52 Week Low 0.82
About
Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.
Analyst Target Price
$6.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-10 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-19 | 2024-11-08 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.03 | -0.05 | 0.09 | -0.1 | -0.12 | -0.14 | -0.19 | -0.22 | -0.28 | -0.13 | -0.11 | -0.1 |
| Estimated EPS | -0.056 | -0.1033 | -0.09 | -0.12 | -0.16 | -0.19 | -0.2 | -0.21 | -0.18 | -0.11 | -0.07 | -0.13 |
| Surprise | 0.026 | 0.0533 | 0.18 | 0.02 | 0.04 | 0.05 | 0.01 | -0.01 | -0.1 | -0.02 | -0.04 | 0.03 |
| Surprise Percentage | 46.4286% | 51.5973% | 200% | 16.6667% | 25% | 26.3158% | 5% | -4.7619% | -55.5556% | -18.1818% | -57.1429% | 23.0769% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.11 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APYX
2026-04-01 13:10:13
Apyx Medical (NASDAQ: APYX) announced that its Renuvion product won the 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener" for the second consecutive year. Renuvion is FDA-cleared for use following liposuction and pairs with the AYON platform to expand physician workflow and procedural options. The award highlights Renuvion's continued leadership in minimally invasive body contouring and its proven clinical impact.
2026-03-22 04:09:02
This article analyzes the historical performance of a $1,000 investment in Apyx Medical Corporation (APYX) over various periods, showing significant volatility with a 189.7% return in the last year but a -61.0% return over five years and -41.1% over ten years. It also provides an overview of Apyx Medical, detailing its focus on surgical aesthetics and advanced energy medical devices through products like Renuvion, J-Plasma, and the AYON Body Contouring System, and outlines its business segments, OEM activities, financial reporting, and regulatory context.
2026-03-17 22:09:10
Moshe Citronowicz, SVP at Apyx Medical, exercised stock options to acquire 37,000 shares of common stock at $1.80 per share under the company's 2015 Share Incentive Plan. This transaction increases his direct ownership to 493,504 shares and is categorized as a routine equity compensation event rather than a market purchase. The Form 4 filing indicates no stock sales alongside this exercise.
2026-03-16 12:39:33
Craig-Hallum has increased its price target for Apyx Medical (APYX) from $5.00 to $6.00, while maintaining a "Buy" rating on the stock. This 20% increase reflects the analyst's positive outlook on the company's growth prospects. Apyx Medical, an energy technology medical device company, specializes in cosmetic and surgical products, with analysts suggesting an average target price of $5.75, indicating a potential upside of 48.96% from its current price.
2026-03-15 05:39:26
Apyx Medical (NASDAQ: APYX) reported its 2025 annual results, highlighting ongoing operating losses but also strategic advancements like the commercial launch of its AYON body contouring system and Renuvion in China. The company implemented significant cost-cutting measures, including a 25% U.S. workforce reduction, which decreased operating expenses. Despite a $6.4 million operating loss and $8.0 million cash outflow from operations, Apyx maintained $31.7 million in cash and remained compliant with its debt covenants, supported by recent equity raises and a new shelf registration for future financing.
2026-03-12 23:09:20
Craig-Hallum has increased its price target for Apyx Medical (APYX) from $5.00 to $6.00, reiterating a "Buy" rating. This 20% increase reflects the analyst's positive outlook on the company's growth prospects. Apyx Medical, an energy technology medical device company, specializes in cosmetic and surgical products like Renuvion and J-Plasma.
